Form 4: MAXCYTE CFO Buys 50,000 Shares

MAXCYTE's Chief Financial Officer, Douglas J Swirsky, acquired 50,000 shares of common stock at $1.29 per share.

Summary

• Douglas J Swirsky, Chief Financial Officer of MAXCYTE, Inc. (MXCT), acquired 50,000 shares of common stock.
• The transaction occurred on August 13, 2025, at a price of $1.29 per share.
• Following this purchase, Mr. Swirsky directly beneficially owns 161,811 shares of MAXCYTE common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 8

Explanation: The Chief Financial Officer's purchase of 50,000 shares of common stock at $1.29 indicates strong insider confidence in MAXCYTE's future prospects and valuation. This is typically viewed as a bullish signal by investors.

Positives

• An insider, the Chief Financial Officer, purchased a significant number of shares (50,000 shares), indicating confidence in the company's future prospects.
• The purchase was made at $1.29 per share.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-planned investment strategy.

Future Outlook

The transaction, being a purchase by a key executive under a 10b5-1 plan, suggests a positive long-term outlook from management, as these plans are typically set up in advance based on a belief in future stock appreciation.

Industry Context

Insider purchases, especially by a CFO, can signal management's belief in the company's undervaluation or strong future performance relative to industry peers. This is a standard insider transaction report.

Comparison to Industry Standards

• This insider purchase by a CFO can be viewed as a strong signal of confidence, particularly if the company's peers are experiencing significant insider selling or if the stock has recently underperformed.

Stakeholder Impact

• Shareholders: Potentially positive signal due to insider confidence, which could lead to increased investor interest and share price appreciation.

Key Dates

Recommendation

The Chief Financial Officer's direct purchase of 50,000 shares at $1.29, executed under a Rule 10b5-1 plan, demonstrates significant insider confidence in MAXCYTE's valuation and future performance. Such a substantial investment by a key executive is typically interpreted by seasoned investors as a strong bullish indicator, suggesting the stock may be undervalued or poised for growth.

Keywords

MAXCYTE, MXCT, Insider Trading, Form 4, Stock Purchase, CFO, Douglas J Swirsky, Equity, Securities, Beneficial Ownership